AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...

AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones. Neomorph will also receive tiered royalties on net ...

AbbVie (ABBV) and Neomorph announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple ...

Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to $1.64 billion in aggregate option fees and milestones, as well as tiered ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

(RTTNews) - AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology ...